Show simple item record

Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex.

dc.contributor.authorEvans, LE
dc.contributor.authorJones, K
dc.contributor.authorCheeseman, MD
dc.date.accessioned2017-04-21T16:31:03Z
dc.date.issued2017-05-04
dc.identifier.citationChemical communications (Cambridge, England), 2017, 53 (37), pp. 5167 - 5170
dc.identifier.issn1359-7345
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/612
dc.identifier.eissn1364-548X
dc.identifier.doi10.1039/c7cc01376k
dc.description.abstractProteins typically carry out their biological functions as multi-protein complexes, which can significantly affect the affinity of small-molecule inhibitors. HSP70 is an important target in oncology, so to study its chemical biology and the drug discovery potential of the HSP70/BAG1 complex, we designed a high-affinity non-nucleotide fluorescence polarisation probe.
dc.formatPrint
dc.format.extent5167 - 5170
dc.languageeng
dc.language.isoeng
dc.publisherROYAL SOC CHEMISTRY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectDNA-Binding Proteins
dc.subjectTranscription Factors
dc.subjectFluorescent Dyes
dc.subjectFluorescence Polarization
dc.subjectMolecular Structure
dc.subjectStructure-Activity Relationship
dc.subjectDose-Response Relationship, Drug
dc.subjectModels, Molecular
dc.subjectHSP70 Heat-Shock Proteins
dc.subjectSmall Molecule Libraries
dc.subjectDrug Discovery
dc.titleTargeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex.
dc.typeJournal Article
dcterms.dateAccepted2017-04-14
rioxxterms.versionofrecord10.1039/c7cc01376k
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfChemical communications (Cambridge, England)
pubs.issue37
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3
pubs.publication-statusPublished
pubs.volume53
pubs.embargo.termsNo embargo
icr.researchteamMedicinal Chemistry 3
dc.contributor.icrauthorEvans, Lindsay
dc.contributor.icrauthorJones, Keith
dc.contributor.icrauthorCheeseman, Matthew


Files in this item

Thumbnail
Name:
HSP70 Chem Comm Resubmission.pdf
Size:
695.5Kb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0